Last updated on August 2019

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia


Brief description of study

Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population).

Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).

Detailed Study Description

Two separate registration trials conducted under one protocol number are proposed to adequately and independently evaluate the addition of glasdegib in intensive and non-intensive chemotherapy populations. Each study will have an experimental treatment arm and a placebo arm. Endpoints are the same for each study except where specifically indicated.

Assignment to the Intensive Study or the Non-Intensive Study will be made by the Investigator based on the 2017 European LeukemiaNet (ELN) recommendations.

Study B1371019 is a randomized (1:1), double-blind, multi-center, placebo controlled study of chemotherapy in combination with glasdegib versus chemotherapy in combination with placebo in adult patients with previously untreated AML.

Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population).

Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).

Clinical Study Identifier: NCT03416179

Find a site near you

Start Over

Keck Hospital of USC

Los Angeles, CA United States
  Connect »

LAC+USC Medical Center

Los Angeles, CA United States
  Connect »

Rrmc - UCLA

Los Angeles, CA United States
  Connect »

UCLA Department of Medicine

Los Angeles, CA United States
  Connect »

UCLA Hematology/Oncology Clinic

Los Angeles, CA United States
  Connect »

UCLA Ronald Reagan Medical Center

Los Angeles, CA United States
  Connect »

UC Irvine Medical Center

Orange, CA United States
  Connect »

Tufts Medical Center

Boston, MA United States
  Connect »

Long Island Jewish Medical Center

New Hyde Park, NY United States
  Connect »

Cleveland Clinic Foundation

Cleveland, OH United States
  Connect »

Swedish Cancer Institute

Seattle, WA United States
  Connect »

Swedish Medical Center

Seattle, WA United States
  Connect »

CHU de Nantes

Nantes cedex 1, France
  Connect »

Institut Gustave Roussy

Villejuif cedex, France
  Connect »

Centennial Medical Center

Nashville, TN United States
  Connect »

Ustavni lekarna

Ostrava - Poruba, Czechia
  Connect »

Klinika hematoonkologie

Ostrava-Poruba, Czechia
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

FSBI RusSRHTI FMBA of Russia

Saint Petersburg, Russian Federation
  Connect »

SBHI CCH No. 40 HD Moscow

Moscow, Russian Federation
  Connect »

V.A Almazov NMRC

Saint Petersburg, Russian Federation
  Connect »

SBHI NNR NN RCH n. a. N.A. Semashko

Nizhniy Novgorod, Russian Federation
  Connect »